logo
Sign in

EVO Stock Price, Chart, Stats & News

909.28M
Market cap
Current P/E
53.48x
Forward P/E

EVO chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
10.82%
Operating margin
-11.30%
Pretax margin
-17.47%
Net margin
-21.02%
Effective tax rate
-20.35%
ROA
-8.97%
ROE
-17.05%
D/E
0.61x
Interest coverage ratio
-5.66x

EVO valuation

P/E
P/S
0.99x
P/B
0.93x
P/CF
528.58x
P/FCF
-8.32x
P/OCF
528.58x
PEG
2.35x
EV multiple
-4.91x

About

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals.

Similar securities

Based on sector and market capitalization

Report issue